Catheter Producer Rests Defense in Product Liability, Negligence Trial

Why It Matters

The outcome will shape how courts allocate responsibility between device manufacturers and end‑users in medical‑device infection cases, influencing future product‑liability strategies across the healthcare sector.

Key Takeaways

• Bard faces first of six bellwether trials in nationwide MDL
• Plaintiff's expert attributes infection to at‑home de‑access, not implantation
• Mayo Clinic's 0.05% infection rate cited, then excluded by judge
• Bard cites <1% infection rate; plaintiffs cite up to 14%
• Jury instructed to disregard Mayo infection‑rate testimony, impacting liability focus

Pulse Analysis

The PowerPort catheter case marks a pivotal moment in the multidistrict litigation that aggregates over 3,000 product‑liability claims against C.R. Bard. By selecting a single plaintiff, Robert Cook, the court aims to establish legal standards that will guide the remaining cases. The trial’s location in the District of Arizona, a hub for medical‑device disputes, underscores the growing scrutiny of manufacturers’ duty to warn and to innovate safer materials. As the first bellwether, its verdict could set precedent for how courts evaluate systemic risk versus isolated user error.

Central to the dispute is the question of where the infection originated. Plaintiff‑side expert Ban Allos testified that the sepsis likely occurred when Cook’s wife disconnected the port at home, suggesting a lapse in de‑access protocol. Bard’s defense, however, emphasizes its low overall infection rate—under 1%—and points to the Mayo Clinic’s exemplary 0.05% rate during implantation. The judge’s decision to strike the Mayo statistic from the record forces the jury to focus on the manufacturer’s alleged failure to provide adequate warnings rather than on comparative hospital performance, sharpening the legal battle over negligence.

Beyond the courtroom, the trial signals broader industry implications. If the jury finds Bard liable despite the at‑home de‑access argument, device makers may face heightened obligations to design ports that are more resistant to user‑handled contamination and to produce clearer, more comprehensive instructional materials. Conversely, a verdict favoring Bard could reinforce the principle that end‑users share responsibility for infection control. Stakeholders—from hospitals to home‑care providers—will watch closely, as the ruling will likely influence risk‑management policies, insurance premiums, and future product‑development roadmaps across the medical‑technology sector.